News
Important Only
Direct Digital Holdings Announces Reverse Stock Split
Jan 8 (Reuters) - Direct Digital Holdings Inc DRCT.O:DIRECT DIGITAL HOLDINGS ANNOUNCES REVERSE STOCK SPLITDIRECT DIGITAL HOLDINGS INC - ANNOUNCED A 55-TO-1 REVERSE STOCK SPLIT OF ALL CLASSES OF ITS COMMON STOCKDIRECT DIGITAL HOLDINGS INC - CLASS A STOCK TO TRADE SPLIT-ADJUSTED FROM JANUARY 12, 2026Reuters
Thu, Jan 8
Haleon PLC Evolution Of Operating Model
Jan 8 (Reuters) - HALEON PLC HLN.L:HALEON PLC - EVOLUTION OF OPERATING MODELHALEON PLC - CREATES NEW CHIEF GROWTH OFFICER ROLEHALEON PLC - CREATING SIX OPERATING UNITSHALEON PLC: CHANGES ARE EXPECTED TO BE IMPLEMENTED BY MID-2026HALEON : CURRENT EMEA & LATAM REGION WILL BE SEPARATED INTO THREE ...Reuters
Thu, Jan 8
China TV shows alleged 'scam centre' kingpin handcuffed and hooded after surprise arrest
Chen indicted in US for financial crimes related to scam centresSoutheast Asia compounds generating billions from online fraud, U.N. saysCambodia orders liquidation of bank founded by ChenPrince Group sanctioned by US, Britain, assets frozen in several countriesBy Xiuhao Chen and Panu Wongcha-um ...Reuters
Thu, Jan 8
Hitachi Ignites Ces 2026 Unveiling Key Collaborations With Nvidia, Google Cloud And Nozomi Networks
Jan 8 (Reuters) - Hitachi Ltd 6501.T:HITACHI IGNITES CES 2026 UNVEILING KEY COLLABORATIONS WITH NVIDIA, GOOGLE CLOUD AND NOZOMI NETWORKS -- BRINGING THE POWER OF AI TO SOCIAL INFRASTRUCTUREReuters
Thu, Jan 8
Coya Therapeutics Announces Results Of Investigator-Initiated Study Of Ld Il-2 And Ctla4-Ig
Jan 8 (Reuters) - Coya Therapeutics Inc COYA.O:COYA THERAPEUTICS ANNOUNCES RESULTS OF INVESTIGATOR-INITIATED STUDY OF LD IL-2 AND CTLA4-IG DEMONSTRATING TREG ENHANCEMENT AND COGNITIVE STABILITY IN FRONTOTEMPORAL DEMENTIA PATIENTSReuters
Thu, Jan 8
Proqr Announces Encouraging Ax-0810 Phase 1
Jan 8 (Reuters) - ProQR Therapeutics NV PRQR.O:PROQR ANNOUNCES ENCOURAGING AX-0810 PHASE 1 SAFETY AND PK DATA, DEVELOPMENT CANDIDATE SELECTIONS, AND 2026 OUTLOOKPROQR THERAPEUTICS NV: INITIAL AX-0810 DATA SHOW NO SAFETY SIGNALS AFTER 4 WEEKS OF DOSING AND PHARMACOKINETICS CONSISTENT WITH NON-CLINICA...Reuters
Thu, Jan 8
Epirium Bio Announces Follow-On Phase 1 Results In Older Adult Participants For MF-300
Jan 8 (Reuters) - EPIRIUM BIO ANNOUNCES FOLLOW-ON PHASE 1 RESULTS IN OLDER ADULT PARTICIPANTS FOR MF-300, A FIRST-IN-CLASS, ORAL 15-PGDH ENZYME INHIBITOR, FOR THE TREATMENT OF SARCOPENIAFurther company coverage: [ ]Reuters
Thu, Jan 8
